 PRA Health Sciences logo 2014 | |
| Company type | Subsidiary |
|---|---|
| Traded as | Nasdaq: PRAH |
| Industry | Pharmaceuticals & Biotechnology |
| Founded | 1976; 48 years ago (1976) Charlottesville, Virginia, U.S. |
| Headquarters | Raleigh, North Carolina, U.S. |
| Area served | Worldwide |
| Key people | Colin Shannon (President and CEO) |
| Revenue |
|
| Number of employees | 17,000+ |
| Parent | ICON plc |
| Website | prahs |
US$ 1.948 billion (2017)PRA Health Sciences was a contract research organization (CRO) with headquarters in Raleigh, North Carolina. It was established in 1976 and acquired by ICON in 2021.
Background
PRA was founded as the Anti-Inflammatory Drug Study Group in 1976, renamed PRA in 1982, as it expanded into other therapeutic areas besides inflammation. In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019. In August 2017, the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million. PRA's 2018 revenue was US$2.87 billion. PRA was acquired by ICON PLC on 1 July 2021.
References
- ^ "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
- "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
- "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
- Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
- "Investors | ICON PLC".
- "ICON acquisition creates world-leading healthcare intelligence and clinical research organisation" (Press release). 1 July 2021.